Background: Metabolic syndrome is a cluster of cardiovascular risk factors, including abdominal obesity,
hyperglycemia, elevated blood pressure and dyslipidemia. Bile acid regulating receptor farnesoid X
receptor plays significant role in treating disorder of glucose and lipid homeostasis. In silico screening,
docking and in-vitro experiments have shown that ivermectin functions as FXR ligand. Objective: This
study aimed to investigate the effect of ivermectin in high fat high carbohydrate diet (HFHC) induced
metabolic syndrome in experimental rats. Experimental work: Metabolic syndrome was induced by
administration of olanzapine (15 mg/kg i.p.) once in a week and HFHC for four weeks followed by
HFHC alone for next eight weeks. The rats were divided into three groups: (I) Control group (II) Model
control (olanzapine (15 mg/kg, i.p.) and HFHC diet) (III) Treatment group was administered Olanzapine
(15 mg/kg, i.p.) and HFHC diet + Ivermectin (0.6 mg/kg, p.o.). Result: HFHC control animals developed
the signs of metabolic syndrome including elevated abdominal fat deposition, impaired glucose tolerance,
hypertension, altered lipid profile (TG, TCHL, LDL, HDL, and VLDL), Liver profile (ALT, AST and ALP) and increased oxidative stress markers. The analysis of left ventricular function (LVEDP, dp/dtmax.,
dp/dtmin) presented promising results. Ivermectin treatment prevented elevation in blood glucose, blood
pressure, oxidative stress and ameliorated lipid profile, liver profile and glucose tolerance indicating the
protective effect of ivermectin in improving of lipid, liver enzyme and glucose levels. Furthermore,
histopathological studies also indicates that ivermectin ameliorates MS. Conclusion: Ivermectin could be
a promising candidate for combatting metabolic syndrome.
Keywords: Metabolic syndrome, FXR, Olanzapine, High fat high carbohydrate (HFHC) diet,
Ivermectin
Publication date: 01/09/2022
https://ijbpas.com/pdf/2022/September/MS_IJBPAS_2022_6392.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.9.6392
